×
About 280 results

ALLMedicine™ Cold Agglutinin Disease Center

Research & Reviews  99 results

Cold agglutinin disease and COVID-19 requiring therapeutic plasma exchange.
https://doi.org/10.1136/bcr-2021-244227
BMJ Case Reports; Ahmed Y, Khandelwal A et. al.

Jul 28th, 2021 - A 70-year-old man with known cold autoimmune haemolytic anaemia was referred to the emergency department with increased shortness of breath on exertion. He had been confirmed positive for non-variant COVID-19 infection 1 week earlier based on naso...

Healthcare resource utilization among patients with cold agglutinin disease in Denmark.
https://doi.org/10.1080/03007995.2021.1960494
Current Medical Research and Opinion; Vágó EK, Nicholson G et. al.

Jul 27th, 2021 - Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia that may manifest in complement-mediated chronic hemolytic anemia, profound fatigue, and transient agglutination-mediated circulatory symptoms. This study compared the hea...

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin d...
https://doi.org/10.1182/blood.2021012039
Blood Jalink M, Berentsen S et. al.

Jul 23rd, 2021 - Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.|2021|Jalink M,Berentsen S,Castillo JJ,Treon SP,Cruijsen M,|

Resolution of serologic problems due to cold agglutinin mediated autoimmune hemolytic a...
https://doi.org/10.1002/jcla.23894
Journal of Clinical Laboratory Analysis; Ying Q, Lv D et. al.

Jul 4th, 2021 - Autoimmune hemolytic anemia (AIHA) is a rare disease characterized by hemolysis caused by autoantibodies against erythrocyte surface antigen. These antibodies can be classified as warm, cold, or mixed types. We report two cases of cold agglutinin ...

Cold agglutinin disease after COVID-19 vaccine.
https://doi.org/10.1111/bjh.17674
British Journal of Haematology; Aoun SA, Motabi I

Jun 28th, 2021 - Cold agglutinin disease after COVID-19 vaccine.|2021|Aoun SA,Motabi I,|

see more →

Clinicaltrials.gov  6 results

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)
https://clinicaltrials.gov/ct2/show/NCT03347396

Apr 24th, 2020 - The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=) 2 gram per deciliter (g/dL) increase in hemoglobin (Hgb) levels or increases Hgb to >= 12 g/dL and obviates the need for blood trans...

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study)
https://clinicaltrials.gov/ct2/show/NCT03347422

Apr 24th, 2020 - The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=)1.5 gram per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglu...

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With wAIHA or CAD
https://clinicaltrials.gov/ct2/show/NCT03226678

Feb 7th, 2020 - This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

Therapy of Chronic Cold Agglutinin Disease With Eculizumab
https://clinicaltrials.gov/ct2/show/NCT01303952

Jul 19th, 2017 - Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent patients with untreated or refractory hemolytic cold agglutinin disease(CAD)

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
https://clinicaltrials.gov/ct2/show/NCT02689986

Jan 9th, 2017 - Prospective, non-randomized multicenter study on the safety and efficacy of combination therapy with bendamustine and rituximab for chronic cold agglutinin disease.

see more →

News  7 results

Sanofi gets priority U.S. FDA review for sutimlimab product
https://www.reuters.com/article/us-sanofi-products/sanofi-gets-priority-u-s-fda-review-for-sutimlimab-product-idUSKBN22Q0JI

May 14th, 2020 - FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau PARIS (Reuters) - French healthcare company Sanofi said on Thursday that the U.S. Food & Drug Administration (FDA) regul...

Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
https://www.mdedge.com/hematology-oncology/article/214191/anemia/sutimlimab-boosts-hemoglobin-quality-life-cold-agglutinin?channel=39313
Neil Osterweil

Dec 12th, 2019 - ORLANDO – An investigational selective inhibitor of the complement pathway, sutimlimab, induced rapid and sustained benefits in patients with cold agglutinin disease, a rare autoimmune hemolytic anemia with no currently approved effective therapie.

Potential treatment on the horizon for cold agglutinin disease
https://www.mdedge.com/hematology-oncology/article/192203/anemia/potential-treatment-horizon-cold-agglutinin-disease
HT Staff

Jan 2nd, 2019 - Red blood cells In a first-in-human trial, sutimlimab rapidly halted hemolysis, corrected anemia, precluded the need for transfusion, and caused no serious adverse effects in patients with cold agglutinin disease. Sutimlimab also “induced clinical.

Cooler Heads Prevail for Preventing Chemo Hair Loss
https://www.medpagetoday.com/hematologyoncology/othercancers/72039

Mar 28th, 2018 - Action Points Scalp cooling was a safe, effective, and well-tolerated method for preventing chemotherapy-induced alopecia. The analysis showed that scalp cooling is significantly more effective with taxane-based compared to anthracycline-based che...

A 51-Year-Old Man With HIV and Suprapubic Pain
https://reference.medscape.com/viewarticle/859634_5

Mar 2nd, 2016 - The median survival for Waldenström macroglobulinemia ranges from 5 to 10 years.[3] In certain patient populations, the disease can be more aggressive.[3] The five adverse covariates that have been identified by the International Prognostic Scorin...

see more →